Central Bank & Trust Co. Has $5.46 Million Stock Holdings in Stryker Corporation $SYK

Central Bank & Trust Co. raised its holdings in shares of Stryker Corporation (NYSE:SYK) by 23.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 15,521 shares of the medical technology company’s stock after acquiring an additional 2,980 shares during the period. Central Bank & Trust Co.’s holdings in Stryker were worth $5,455,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Clayton Financial Group LLC acquired a new stake in shares of Stryker during the third quarter worth $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at about $27,000. Elevation Point Wealth Partners LLC acquired a new position in Stryker in the second quarter valued at about $28,000. Kilter Group LLC bought a new position in Stryker during the second quarter worth about $29,000. Finally, Howard Hughes Medical Institute bought a new position in Stryker during the second quarter worth about $29,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reports containment of the cybersecurity incident and progress in system restoration; operations are stabilizing, which reduces near-term disruption risk. Stryker reports progress in restoration efforts after cyberattack, operations continue to stabilize
• Positive Sentiment: Market reaction showed short-term relief: several outlets noted shares briefly rose after the company said the incident was contained, reflecting lowered immediate operational risk. Stryker shares climb after company says cybersecurity incident contained
• Neutral Sentiment: Stryker announced its 2026 Annual Meeting of Shareholders — routine corporate governance item with limited direct market impact. Stryker announces Annual Meeting of Shareholders
• Neutral Sentiment: Analyst / sector comparisons (Envista, Intuitive Surgical) discuss valuation and growth positioning versus Stryker; useful for longer-term allocation decisions but not the day’s price driver. NVST or SYK: Which Is the Better Value Stock Right Now? Intuitive Surgical vs. Stryker: Which Surgical Tech Stock Leads?
• Negative Sentiment: Coverage emphasizes that attackers (including state-linked criminal groups) are mounting disruptive, multifaceted campaigns that can extract leverage beyond data theft — raising the risk of longer recovery costs, regulatory scrutiny, and reputation/competitive impacts. Stryker Cyberattack Highlights Criminal Focus on Enterprise Systems
• Negative Sentiment: Company had disclosed the incident to the SEC earlier in March; lingering uncertainty around remediation costs, potential supply/servicing disruption, and any customer impact keeps downside risk for the stock until full restoration and forensic results are confirmed. Stryker Addresses and Contains Recent Cybersecurity Incident

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research note on Friday, January 30th. Sanford C. Bernstein lifted their price objective on shares of Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price for the company in a research note on Friday, December 19th. UBS Group cut their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Finally, The Goldman Sachs Group set a $399.00 price target on shares of Stryker in a research report on Friday, January 9th. Fourteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $427.50.

Stryker Trading Down 1.0%

NYSE SYK opened at $332.48 on Tuesday. Stryker Corporation has a one year low of $328.23 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The firm has a market cap of $127.24 billion, a P/E ratio of 39.58, a P/E/G ratio of 1.96 and a beta of 0.85. The stock’s 50-day moving average is $362.68 and its 200-day moving average is $365.29.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.01 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio is 41.90%.

Insider Activity

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.20% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.